Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial-Reference-Cited by-同舟云学术

Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial

Published:2013-04-15 Issue:6 Volume:104 Page:718-724
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Giessen Clemens¹,Laubender Ruediger P.,Fischer von Weikersthal Ludwig²,Schalhorn Andreas¹,Modest Dominik P.¹,Stintzing Sebastian¹,Haas Michael¹,Mansmann Ulrich R.³,Heinemann Volker¹

Affiliation:

1. Department of Medical Oncology; Klinikum Grosshadern and Comprehensive Cancer Center; Ludwig-Maximilians-University of Munich; Munich; Germany

2. Klinikum Sankt Marien; Onkologisches Zentrum; Amberg; Germany

3. Institute of Medical Informatics, Biometry, and Epidemiology (IBE); Faculty of Medicine; Ludwig-Maximilians-University Munich; Munich; Germany

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12148/fullpdf

Reference20 articles.

1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

2. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial);Piessevaux;Ann Oncol,2009

3. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study;Piessevaux;Ann Oncol,2010

4. Piessevaux H Van Cutsem E Bokemeyer C Schlichting M Heeger S Tejpar S Early tumor shrinkage and clinical outcome in metastatic colorectal cancer: Analysis of predictive utility in the CRYSTAL and OPUS studies 2012

5. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer;Glimelius;Ann Oncol,2008

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma;BMC Gastroenterology;2024-09-02

2. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407;Pancreatology;2024-09

3. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study;Clinical Colorectal Cancer;2024-05

4. First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study;Esophagus;2024-04-12

5. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab;International Journal of Clinical Oncology;2024-04-08